You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

Molecularly Guided Therapies for Metastatic Colorectal Cancer: Choose Your Marker to Treat

  • Authors: Julien Taieb, MD, PhD; Chiara Cremolini, MD, PhD; Harpreet Wasan, MD; Eric Van Cutsem, MD, PhD; Sebastian Stintzing, MD
  • CPD Released: 4/5/2023
  • Valid for credit through: 4/5/2024
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.50 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for an international audience of non-US healthcare professionals, specifically gastroenterologists, hematology/oncology specialists, pathologists, and any other healthcare specialists involved in the care of patients with metastatic colorectal cancer (mCRC).

The goal of this activity is for learners to be better able to apply molecular testing in their patients with mCRC and use the results to inform treatment strategies with current and emerging targeted therapies.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Molecular testing requirements in patients with mCRC
    • Impact of RAS mutation status on the treatment of mCRC
    • Available clinical data with targeted therapies for human epidermal growth factor receptor 2 (HER2)-amplified mCRC
  • Have greater competence related to
    • Selecting therapy according to BRAF mutation status in a patient with mCRC
    • Selecting therapy according to microsatellite instability/mismatch repair deficient (MSI/dMMR) status in a patient with mCRC
    • Selecting therapy in patients with neurotrophic tyrosine receptor kinase (NTRK) fusion-positive mCRC


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.


Faculty

  • Julien Taieb, MD, PhD

    Professor
    Université Paris Cite (Descartes)
    Hôpital Européen Georges-Pompidou
    Paris, France

    Disclosures

    Julien Taieb, MD, PhD has the following relevant financial relationships:
    Consultant or advisor for: AstraZeneca; Astellas Pharma, Inc.; Bristol Myers Squibb Company; Merck Sharp & Dohme; Merck; Novartis; Pierre Fabre; Roche; SERVIER
    peaker or member of speakers bureau for: AstraZeneca; Astellas Pharma, Inc.; Bristol Myers Squibb Company; Merck Sharp & Dohme; Merck; Novartis; Pierre Fabre; Roche; SERVIER
    Research funding from: Pierre Fabre

  • Chiara Cremolini, MD, PhD

    Professor of Medical Oncology
    University of Pisa
    Pisa, Italy

    Disclosures

    Chiara Cremolini, MD, PhD has the following relevant financial relationships:
    Consultant or advisor for: Amgen Inc.; Merck; Pierre Fabre; SERVIER; Nordic Pharma
    Speaker or member of speakers bureau for: Bayer; Merck Sharp & Dohme; SERVIER; Pierre Fabre
    Research funding from: Bayer; Merck; SERVIER

  • Harpreet Wasan, MD

    Professor and Consultant in Medical Oncology
    Division of Cancer
    Hammersmith Hospital
    Imperial College Healthcare London
    London, United Kingdom

    Disclosures

    Harpreet Wasan, MD, has the following relevant financial relationships:
    Consultant or advisor for: ARCAD (Pancreas Academic); Bayer; Bristol Myers Squibb Company (Celgene Corporation); BTG International Ltd.; Celgene Corporation; Erytech Pharma; FM; Genentech; Incyte Corporation; NICE/BSI expert; Merck KGaA; ONCOSIL; SERVIER; SIRTEX Medical; Roche; Pierre Fabre; Pfizer, Inc.; Zymeworks
    Speaker or member of speakers bureau for: Bayer; Bristol Myers Squibb Company (Celgene Corporation); BTG International Ltd.; Erytech Pharma; FM; Genentech; Incyte Corporation; Merck KGaA; Roche; SERVIER; SIRTEX Medical; Pierre Fabre; Pfizer, Inc.; Zymeworks
    Research funding from: Merck Serono; Merck Sharp & Dohme; Pfizer, Inc.; SIRTEX Medical

  • Eric Van Cutsem, MD, PhD

    Professor of Medicine
    Head of Digestive Oncology
    University Hospital Leuven
    Leuven, Belgium

    Disclosures

    Eric Van Cutsem, MD, PhD has the following relevant financial relationships:
    Consultant or advisor for: AbbVie Inc.; ALX; Array BioPharma; Astellas Pharma, Inc.; AstraZeneca; Bayer; BeiGene (Beijing) Co., Ltd; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Company; Daiichi Sankyo, Inc.; Eli Lilly and Company; GlaxoSmithKline; Incyte Corporation; Ipsen; Merck Sharp & Dohme; Merck KGaA; Mirati; Nordic Bioscience; Novartis; Pierre Fabre; Pfizer, Inc.; Roche; Seagen Inc.; SERVIER; Taiho Pharmaceutical Co., Ltd; Takeda; Terumo Medical Corporation; Zymeworks
    Research funding from: Amgen Inc.; Bayer; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb; Eli Lilly and Company; Ipsen; Merck KGaA; Merck Sharp & Dohme; Novartis; Roche; SERVIER

  • Sebastian Stintzing, MD

    Professor of Medicine
    Head of the Department of Hematology,
    Oncology, and Cancer Immunology (CCM)
    Charité-Universitaetsmedizin Berlin
    Berlin, Germany

    Disclosures

    Sebastian Stintzing, MD, has the following relevant financial relationships:
    Consultant or advisor for: Amgen, Inc.; AstraZeneca; Bayer; Bristol Myers Squibb Company; Eli Lilly and Company; ESAI; Merck KGaA; Merck Sharp & Dohme; Pierre Fabre; Roche; Sanofi; SERVIER; Taiho Pharmaceutical Co., Ltd.; Takeda
    Speaker or member of speakers bureau for: Amgen, Inc.; AstraZeneca; Bayer; Bristol Myers Squibb Company; Eli Lilly and Company; ESAI; Isofol; LEO Pharma, Inc.;
    Research funding from: Merck KGaA; Pierre Fabre; SERVIER; Roche

Editors

  • Keisha Peters, MSc

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Keisha Peters, MSc, has no relevant financial relationships.

  • Eloise Ballard, PhD

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Eloise Ballard, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

Molecularly Guided Therapies for Metastatic Colorectal Cancer: Choose Your Marker to Treat

Authors: Julien Taieb, MD, PhD; Chiara Cremolini, MD, PhD; Harpreet Wasan, MD; Eric Van Cutsem, MD, PhD; Sebastian Stintzing, MDFaculty and Disclosures

CPD Released: 4/5/2023

Valid for credit through: 4/5/2024

processing....

  • Print